Morgan Stanley has increased its price target for CVS Health (CVS, Financial), raising it from $68 to $80. The investment firm maintains an Overweight rating on the stock, reflecting a positive outlook for the company.
The analyst notes that policy considerations will remain a significant factor across the Healthcare Services and Technology sectors, affecting various players to varying degrees. However, attention will also be directed toward identifying trends in underlying utilization as the market enters the first quarter. This focus spans multiple areas, including managed care organizations (MCOs), distributors, healthcare providers, clinical laboratories, as well as the animal and dental health sectors.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CVS Health Corp (CVS, Financial) is $72.02 with a high estimate of $85.00 and a low estimate of $48.01. The average target implies an upside of 4.07% from the current price of $69.20. More detailed estimate data can be found on the CVS Health Corp (CVS) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CVS Health Corp's (CVS, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CVS Health Corp (CVS, Financial) in one year is $87.74, suggesting a upside of 26.79% from the current price of $69.2. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CVS Health Corp (CVS) Summary page.
